Fujian Cosunter Pharmaceutical Co Ltd (300436) — Working Capital to Net Assets Ratio
Fujian Cosunter Pharmaceutical Co Ltd (300436) has a Working Capital to Net Assets ratio of 2.7% as of March 2026. Working capital of CN¥8.63 Million (current assets of CN¥526.34 Million minus current liabilities of CN¥517.71 Million) is measured against net assets of CN¥316.18 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Fujian Cosunter Pharmaceutical Co Ltd (300436) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Fujian Cosunter Pharmaceutical Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Fujian Cosunter Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 2.7%, reflecting working capital of CN¥8.63 Million against net assets of CN¥316.18 Million CNY. Check Fujian Cosunter Pharmaceutical Co Ltd (300436) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Fujian Cosunter Pharmaceutical Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Fujian Cosunter Pharmaceutical Co Ltd worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 11.4% | CN¥39.40 Million | CN¥346.30 Million | CN¥511.42 Million | CN¥472.02 Million | ▲ +53.6 pp |
| 2024 | -42.2% | CN¥-167.48 Million | CN¥396.78 Million | CN¥407.30 Million | CN¥574.78 Million | ▼ -16.1 pp |
| 2023 | -26.1% | CN¥-148.48 Million | CN¥569.24 Million | CN¥449.29 Million | CN¥597.76 Million | ▼ -24.6 pp |
| 2022 | -1.5% | CN¥-14.25 Million | CN¥955.62 Million | CN¥394.30 Million | CN¥408.55 Million | ▼ -25.1 pp |
| 2021 | 23.6% | CN¥247.58 Million | CN¥1.05 Billion | CN¥549.89 Million | CN¥302.31 Million | ▲ +29.9 pp |
| 2020 | -6.3% | CN¥-36.89 Million | CN¥581.99 Million | CN¥257.43 Million | CN¥294.32 Million | ▲ +0.1 pp |
| 2019 | -6.4% | CN¥-36.94 Million | CN¥573.74 Million | CN¥197.98 Million | CN¥234.92 Million | ▼ -1.1 pp |
| 2018 | -5.3% | CN¥-30.08 Million | CN¥562.35 Million | CN¥206.10 Million | CN¥236.17 Million | ▼ -60.5 pp |
| 2017 | 55.2% | CN¥304.73 Million | CN¥552.05 Million | CN¥472.85 Million | CN¥168.12 Million | ▼ -4.2 pp |
| 2016 | 59.4% | CN¥328.17 Million | CN¥552.36 Million | CN¥460.54 Million | CN¥132.38 Million | ▼ -12.9 pp |
| 2015 | 72.3% | CN¥375.46 Million | CN¥519.20 Million | CN¥440.50 Million | CN¥65.04 Million | ▲ +34.5 pp |
| 2014 | 37.8% | CN¥59.29 Million | CN¥156.87 Million | CN¥111.19 Million | CN¥51.90 Million | ▼ -7.5 pp |
| 2013 | 45.3% | CN¥64.81 Million | CN¥143.10 Million | CN¥103.78 Million | CN¥38.97 Million | ▲ +10.0 pp |
| 2012 | 35.3% | CN¥38.29 Million | CN¥108.59 Million | CN¥66.27 Million | CN¥27.98 Million | ▲ +4.1 pp |
| 2011 | 31.1% | CN¥20.36 Million | CN¥65.43 Million | CN¥51.48 Million | CN¥31.12 Million | — |